The next chapter of the brave new world of global P&MA under MFN: Latest developments and Simon-Kucher perspectives

Published on September 11, 2026

The proposed US Most Favored Nation (MFN) policy is still making headlines and has already been reshaping global pricing and market access (P&MA) strategies.  

Join our upcoming webinar to explore Simon-Kucher’s latest perspectives on the evolving MFN landscape, the potential implications of the US midterm election results, the developments and adaptations observed in HTA and P&MA processes across individual ex-US markets, and how pharma companies are responding to these changes. 

Our experts will discuss the potential impact of these policies on global P&MA dynamics, as well as practical approaches to adapting commercial…

MFN Webinar Dec 3

Continue reading on website
Other news

Corporate & Business Banking Webinarserie: Von Produktsilos zu integrierten Business-Banking-Angeboten

September 10, 2026
Wie gelingt profitables Wachstum im Corporate & Business Banking? Corporate & Business Banking steht vor einem tiefgreifenden Wandel: intensiver Wettbewerb, steigender Margendruck, neue regulatorische und technologische Rahmenbedingungen sowie veränderte Kundenerwartungen erhöhen den Handlungsdruck. Gleichzeitig eröffnen AI, neue Datenquellen und digitale Geschäftsmodelle erhebliche Chancen, Kunde

MFN as a stress test for pharma price governance

October 2, 2026
External price referencing is re-entering the US debate, but its implications extend far beyond policy mechanics. Most Favored Nation (MFN) proposals can directly link US and ex-US drug prices, creating new cross-market risks that directly affect US revenue. For pharma leaders, it can serve as a catalyst to stress test global pricing governance across list, net, and realized metrics.MFN policy: Th